A Phase 3 interventional study of BDP HFA and Placebo nasal aerosol in Seasonal Allergic Rhinitis and SAR, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 45 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2015-02-20.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 23rd largest by enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2011, is one of 47 in phase 3, and was the 75th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 48 · Phase 4 18
First in 2001; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 715 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 446 across the 101 interventional studies, 92 across the 5 observational. Of the 100 that completed or were terminated, 56 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 8 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic, Seasonal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add it to your calendar (.ics) → With an account.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of an investigational nasal aerosol at two doses compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis in children (6-11 years of age).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
Drug: BDP HFA
Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
Drug: BDP HFA
Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
Drug: Placebo nasal aerosol
BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
Also known as: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol, QNASL®
Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment
Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported rTNSS over the 4 days prior to randomization.
Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment
Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported iTNSS over the 4 days prior to randomization.
Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15
| Milestone | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily |
|---|---|---|---|
| Started | 239 | 242 | 234 |
| Safety population | 239 | 241 | 234 |
| Itt population | 238 | 241 | 234 |
| Completed | 235 | 234 | 227 |
| Not completed | 4 | 8 | 7 |
| Withdrew: Adverse event | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Other | 0 | 4 | 3 |
Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported iTNSS over the 4 days prior to randomization.
| units on a scale | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily |
|---|---|---|---|
| Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment | -1.6 ± 0.13 | -1.7 ± 0.13 | -1.0 ± 0.13 |
Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported rTNSS over the 4 days prior to randomization.
| units on a scale | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily |
|---|---|---|---|
| Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment | -1.9 ± 0.14 | -2.0 ± 0.14 | -1.2 ± 0.14 |
Collected over Day 1 to Week 6. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP HFA 80 mcg/Day | — | 0/239 (0%) | 0/239 (0%) |
| BDP HFA 160 mcg/Day | — | 0/241 (0%) | 0/241 (0%) |
| Placebo Nasal Aerosol Once Daily | — | 0/234 (0%) | 0/234 (0%) |
Safety population: the safety population included all randomized participants who received at least one dose of randomized study medication.
| Age, Continuous(years) | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 1.73 | 9.1 ± 1.62 | 9.1 ± 1.65 | 9.0 ± 1.67 |
| Sex: Female, Male(Participants) | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily | Total |
|---|---|---|---|---|
| Female | 105 | 116 | 111 | 332 |
| Male | 134 | 125 | 123 | 382 |
| Race/Ethnicity, Customized(participants) | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily | Total |
|---|---|---|---|---|
| White | 169 | 172 | 164 | 505 |
| Black or African American | 56 | 55 | 52 | 163 |
| Asian | 2 | 4 | 6 | 12 |
| Other | 12 | 10 | 12 | 34 |
| Race/Ethnicity, Customized(participants) | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily | Total |
|---|---|---|---|---|
| Hispanic or Latino | 40 | 53 | 45 | 138 |
| Not Hispanic or Latino | 199 | 188 | 189 | 576 |
| Body Mass Index(kg/m^2) | BDP HFA 80 mcg/Day | BDP HFA 160 mcg/Day | Placebo Nasal Aerosol Once Daily | Total |
|---|---|---|---|---|
| Mean | 19.0 ± 4.15 | 19.4 ± 4.52 | 19.1 ± 4.72 | 19.1 ± 4.46 |
The record gives a start of Mar 2011, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 3 years 7 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Rhinitis, Allergic, Seasonal →
Teva Branded Pharmaceutical Products R&D, Inc. →